NCT04485013
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advance Solid Refractory/Resistant Malignancies
Associated Conditions
Multiple Tumor TypesSponsor
Tizona Therapeutics, Inc.
This study is currently enrolling.